<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096962</url>
  </required_header>
  <id_info>
    <org_study_id>2021/2</org_study_id>
    <nct_id>NCT05096962</nct_id>
  </id_info>
  <brief_title>COVID-19: SARS-CoV-2-CZ-PREVAL-II Study</brief_title>
  <official_title>SARS-CoV-2-CZ-PREVAL-II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Health Information and Statistics of the Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The National Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Institute of Molecular and Translational Medicine, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Olomouc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Clinical and Experimental Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomayer University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Czech Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Palacky University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Health Information and Statistics of the Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants&#xD;
      with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific&#xD;
      subjects cohorts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants&#xD;
      with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in four specific&#xD;
      cohorts: participants with chronic illness, healthy volunteers participating in the Study of&#xD;
      the Czech Academy of Science, healthcare workers, and healthy volunteers that participated in&#xD;
      the &quot;Herd Immunity Study SARS-CoV-2-CZ-Preval&quot; in May 2020.&#xD;
&#xD;
      The primary aim of the study is to estimate the number of people with&#xD;
      anti-SARS-CoV-2-antibodies, i.e., people with COVID-19 history, or with vaccination against&#xD;
      COVID-19.&#xD;
&#xD;
      Antibodies test will focus on two main proteins of virus SARS-CoV-2: S-protein and N-protein.&#xD;
&#xD;
      The secondary aims of the study are:&#xD;
&#xD;
        -  quantitative analysis of cellular immunity and the other relevant markers,&#xD;
&#xD;
        -  estimation of the proportion of participants with asymptomatic COVID-19 infection&#xD;
&#xD;
        -  quantification of anti-SARS-CoV-2 antibodies and cell immunity according to individual&#xD;
           risk factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of a number of subjects with IgG anti-SARS-CoV-2 antibodies</measure>
    <time_frame>September-October 2021</time_frame>
    <description>The primary outcome is to quantify the prevalence of participants with IgG anti-SARS-CoV-2 antibodies in the specified subjects cohorts.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">9300</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Arm IKEM</arm_group_label>
    <description>Arm IKEM (Institute for Clinical and Experimental Medicine) is represented by two subcohorts:&#xD;
participants with chronic illness (adults only), which are part of the research project of the Institute of Clinical and Experimental Medicine (the expected number of participants in the study - 3 000)&#xD;
healthy subjects from the Study of Czech Academy of Science, who are following up in the Institute of Clinical and Experimental Medicine (the expected number of subjects in the study - 2000) The subjects will be contacted based on the Hospital study database.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm FTN</arm_group_label>
    <description>Arm FTN (Thomayer University Hospital) is represented by the healthcare staff of the Hospital (the expected number of subjects in the study - 1800).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Olomouc</arm_group_label>
    <description>Arm Olomouc is represented by participants, who participated in the Study &quot;Herd Immunity Study SARS-CoV-2-CZ-Preval&quot; in May 2020 and at the same time subjects who will be willing to participate in this study. The involvement of subjects from two localities is expected:&#xD;
Olomouc&#xD;
Litovel, Uničov and Červenka. The expected number of subjects in the study is approximately 2500.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantitative analysis of SARS-CoV-2 antibodies</intervention_name>
    <description>The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).</description>
    <arm_group_label>Arm FTN</arm_group_label>
    <arm_group_label>Arm IKEM</arm_group_label>
    <arm_group_label>Arm Olomouc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cellular immunity</intervention_name>
    <description>Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.</description>
    <arm_group_label>Arm FTN</arm_group_label>
    <arm_group_label>Arm IKEM</arm_group_label>
    <arm_group_label>Arm Olomouc</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma sampling will be archived in the biobank for subsequent analyses.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is composed of different cohorts of people. The first cohort, Arm&#xD;
        IKEM, is chosen from a database of chronically ill patients and subjects involved in the&#xD;
        sociological study of the Czech Academy of Sciences. The second cohort, Arm FTN, is chosen&#xD;
        from healthcare workers of the Thomayer University Hospital. The third cohort, Arm Olomouc,&#xD;
        is composed of volunteers who participated in the Study SARS-CoV-2-CZ-Preval in May 2020.&#xD;
&#xD;
        All subjects will be contacted by email, phone, or SMS.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed Informed consent&#xD;
&#xD;
          -  willingness to complete the study questionnaire&#xD;
&#xD;
          -  demographic criteria - age 18 years old and more&#xD;
&#xD;
          -  clinical criteria - without acute health problems&#xD;
&#xD;
          -  time criteria - sample collection in the defined period time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marián Hajdúch, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Molecular nad Translational Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Věra Adámková, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Clinical and Experimental Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markéta Ibrahimová, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomayer University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbora Macková, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The National Institute of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ladislav Dušek, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Health Information and Statistics of the Czech Republic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Health Information and Statistics of the Czech Republic</name>
      <address>
        <city>Prague</city>
        <zip>128 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibodies</keyword>
  <keyword>cell immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>It is not yet known if there will be a plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

